MARKET

TEVA

TEVA

Teva Pharm
NYSE
13.25
+0.24
+1.84%
After Hours: 13.30 +0.05 +0.38% 19:30 04/25 EDT
OPEN
12.81
PREV CLOSE
13.01
HIGH
13.30
LOW
12.80
VOLUME
8.52M
TURNOVER
0
52 WEEK HIGH
14.47
52 WEEK LOW
7.09
MARKET CAP
15.01B
P/E (TTM)
-26.5212
1D
5D
1M
3M
1Y
5Y
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna to offer close copies of AbbVie's arthritis drug Humira with $0 copay at specialty pharmacy beginning in June. The company will stock biosimilar versions of the drug at its Accredo pharmacy in the U.S. Cigna says the move should save eligible patients $3,500 per year. Abbvie has held onto 98% of the Humira market.
Reuters · 16h ago
The Sound Shore Fund Q1 2024 Letter To Shareholders
The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10% in the first quarter of 2024. The Fund's strong first quarter 2024 gain was substantially ahead of both the Russell Value and S&P 500 indices. The fund's portfolio return was driven by 12 holdings from seven different sectors.
Seeking Alpha · 2d ago
Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex
NASDAQ · 3d ago
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
The U.S. Supreme Court has reportedly declined to review Vanda Pharmaceuticals Inc’s attempt to revive patents for its sleep-disorder medication Hetlioz. Vanda had previously had its patents invalidated in a legal battle with generic drugmakers Teva Pharmaceutical Industries.
Benzinga · 3d ago
BUZZ-Vanda Pharma falls as Supreme Court rejects case over sleep-drug patents
U.S. Supreme Court declines to hear bid by Vanda to revive patents for its sleep-disorder drug Hetlioz. Shares of drugmaker Vanda Pharmaceuticals down 6.1% to $4.80. Patents were previously declared invalid in dispute with generic drugmakers Teva.
Reuters · 3d ago
'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
U.S. Supreme Court declines to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz. The company's patents were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling.
Benzinga · 3d ago
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents. Vanda wanted to revive patents for its drug Hetlioz that were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling against the company.
Reuters · 3d ago
US Supreme Court reportedly declines to hear Vanda patent case
US Supreme Court reportedly declines to hear Vanda Pharmaceuticals' patent case. Vanda had appealed to the high court after a lower court ruled in 2022 that the company's patents for its sleep-wake disorder drug Hetlioz were invalid. The FDA declined to approve a label expansion for the drug last month.
Seeking Alpha · 3d ago
More
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Webull offers Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE: TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.